Contact Us

Phone: 1-866-61-EISAI (1-866-61-34724)

Fax: 1-866-57-EISAI (1-866-57-34724)

Monday - Friday 8AM - 8PM ET


Coverage Policy

The information displayed below pertains specifically to the Physician Office setting of care. For information tailored to the Hospital Outpatient setting or Ambulatory Surgery Center setting, please select the appropriate tab to the right. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. See below

ALOXI® is eligible for coverage under most state Medicaid programs. However, coverage and reimbursement will vary from state to state as each Medicaid program establishes its own eligibility standards and determines the type, amount, duration, and scope of services. Reimbursement rates for services will also vary from state to state. Some Medicaid programs may cover ALOXI® as a medical benefit, pharmacy benefit, or both. In addition, state Medicaid programs may apply coverage and utilization restrictions such as prior authorization or step therapy.


For more information on Medicaid-specific coverage for ALOXI®, contact the Eisai Assistance Program at 1-866-61-EISAI or 1-866-61-34724.

 

Payor Reimbursement

Medicaid reimbursement for ALOXI® administered in the physician office setting varies by state Medicaid program. Some Medicaid programs may base reimbursement on ASP plus 4%. Others may base reimbursement on a percent markup or markdown of Average Wholesale Price (AWP) or Wholesale Acquisition Cost (WAC). Drug reimbursement rates may be updated by state Medicaid programs on a monthly, quarterly, or yearly basis.

Administration Services

Medicaid reimbursement for ALOXI® drug administration services provided in the physician office setting varies by state Medicaid program. Many states base reimbursement on a statewide fee schedule that may be updated on a quarterly or annual basis.

 

Indication

ALOXI® (palonosetron HCl) injection 0.25 mg is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.


Important Safety Information:


For more information about ALOXI® please see full Prescribing Information.




Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.

This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries.

ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.

Distributed and marketed by Eisai Inc. CORP74AR6 ©2012 Eisai Inc. All rights reserved.

This site was last modified on : December 19, 2011 at 5:45pm ET